Drugs / VV261
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07710326 | Aug → Nov 2026 expected | — | Vigonvita Life Sciences | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07302269 | Jan → Jun 2026 overdue | — | Vigonvita Life Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VV261 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07302269 ↗ |
| Route | Oral | “2 subjects will receive VV261 5mg, orally” NCT07302269 ↗ |